ArticleTranslational pediatrics2026
A m6A/m1A/m5C-related eight-gene signature predicts prognosis and correlates with immune microenvironment in pediatric acute myeloid leukemia.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: N6-methyladenosine (m6A), 5-methylcytosine (m5C) and N1-methyl-adenosine (m1A) are among predominate forms of RNA methylations implicated in the progression of cancer. The study aims to dissect the associations of m6A/m1A/m5C genes with survival, tumor microenvironment (TME) and predicted immunotherapy response in pediatric patients with acute myeloid leukemia (AML). Methods: RNA sequencing (RNA-seq) data were downloaded from Xena database. Differentially expressed m6A/m1A/m5C genes were filtered between dead and alive samples. Least absolute shrinkage and selection operator (LASSO) cox regression analysis was used to identify optimal prognostic genes and construct a risk-score model. TME characteristics and immunotherapy response were analyzed across different risk subgroups. Results: Twenty-five differentially expressed m6A/m1A/m5C genes were identified. Eight optimal prognostic genes were selected via LASSO and an 8-gene-based prognostic model was built. It effectively distinguished high- from low-risk patients [survival difference: P value =6.328e-07, area under the curve (AUC) value =0.861 (0.820, 0.778)], with valid verification in a validation dataset [survival difference: P value =2.677e-02, AUC value =0.774 (0.625, 0.833)]. The risk score was an independent prognostic factor and a composite nomogram could more accurately predict survival probability. Low-risk patients had significantly higher levels of monocytes and lower tumor purity compared to high-risk patients. A trend toward differential risk scores was observed between predicted immunotherapy responders and non-responders. Conclusions: We propose an 8-gene prognostic signature related to m6A/m5C/m1A and a risk-score model for assessing prognosis in pediatric AML. These genes may serve as promising preliminary prognostic biomarkers and warrant further exploration as potential immunotherapy targets for pediatric AML, pending validation in larger-scale prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.